文献速递针灸推拿中医骨伤中医康复

浮针治疗膝骨关节炎疼痛与身体功能的系统评价与Meta分析

Effectiveness of Fu's subcutaneous needling on pain and physical function in patients with knee osteoarthritis: A systematic review and meta-analysis.
PubMed 文献 · Complement Ther Med · 2025-08-20

该系统评价与Meta分析纳入30项RCT共2169例膝骨关节炎患者,比较浮针与电针、针刺等疗法。浮针在改善WOMAC评分、缓解疼痛、降低炎症因子及提高总有效率方面显示显著优势,但证据质量为中等,短期疗效获支持,长期获益待验证。

要点

  • 浮针可显著改善膝骨关节炎患者WOMAC评分和疼痛视觉模拟评分。
  • 浮针降低IL-1β、IL-6、TNF-α水平并提高总有效率。
  • 证据质量中等,短期有效,长期获益需标准化方案验证。

核心结论

  • 浮针可作为膝骨关节炎的辅助疗法,中等质量证据支持其短期缓解疼痛和改善功能的疗效。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Cochrane Library、Embase、Web of Science等数据库至2024年7月20日,纳入30项RCT共2169例患者,使用Stata 15.0分析。

主要发现

  • 与电针、针刺等疗法相比,浮针降低WOMAC评分[SMD=-1.69(-2.15至-1.23),I²=89.8%,P<0.001]。
  • 浮针缓解疼痛(视觉模拟评分)[SMD=-1.77(-2.14至-1.40),I²=89.8%,P<0.001]。
  • 浮针降低IL-1β[SMD=-1.65(-2.36,-0.94),I²=91.9%,P<0.001]、IL-6[SMD=-3.93(-5.08,-2.78),I²=96.7%,P<0.001]和TNF-α[SMD=-2.65(-3.46,-1.83),I²=94.8%,P<0.001]。
  • 浮针提高总有效率[OR=4.17,95%CI:3.05-5.68,I²=0.0%,P<0.001]。

临床怎么用

  • 临床可考虑将浮针作为膝骨关节炎的辅助治疗,用于短期疼痛缓解和功能改善。

局限性

  • 证据质量为中等,需通过标准化方案进一步验证长期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to evaluate the efficacy of Fu's subcutaneous needling (FSN) for knee osteoarthritis (KOA) via a meta-analysis. METHODS: Randomized controlled trials (RCTs) of FSN for KOA were searched in PubMed, Cochrane Library, Embase, Web of Science, and other databases up to July 20, 2024. Stata 15.0 was leveraged for data analysis. RESULTS: 30 RCTs were included, involving 2169 individuals. Compared to electroacupuncture, acupuncture, and other therapies, FSN demonstrated significant benefits in reducing the Western Ontario and McMaster Universities Arthritis Index score (WOMAC, improved physical function) [SMD= -1.69 (-2.15 to -1.23), I² = 89.8 %, P < 0.001] and relieving pain (the visual analog scale) [SMD = -1.77( -2.14 to -1.40); I² = 89.8 %, P < 0.001]. Additionally, FSN was more effective in reducing inflammatory cytokine levels, such as interleukin 1β [SMD = -1.65 (-2.36, -0.94); I² = 91.9 %, P < 0.001], interleukin-6 [SMD = -3.93 (-5.08, -2.78); I² = 96.7 %, P < 0.001], and tumor necrosis factor-α [SMD = -2.65 (-3.46, -1.83); I² = 94.8 %, P < 0.001], and increasing the total effective rate [OR = 4.17, 95 % CI: 3.05-5.68; I² = 0.0 %, P < 0.001]. CONCLUSIONS: FSN shows promise as an adjuvant therapy for KOA, with moderate-quality evidence supporting its short-term efficacy in pain relief and functional improvement. Further validation through standardized protocols is required to determine its long-term benefits.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Liu T, Zhi W, Wang X, et al. Effectiveness of Fu's subcutaneous needling on pain and physical function in patients with knee osteoarthritis: A systematic review and meta-analysis. Complement Ther Med. 2025. PMID: 40846208. doi:10.1016/j.ctim.2025.103233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。